During our continued search for strong
skin whitening agents over the past ten years, we have investigated the efficacies of many
tyrosinase inhibitors containing a common (E)-β-phenyl-α,β-unsaturated carbonyl scaffold, which we found to be essential for the effective inhibition of mushroom and mammalian tyrosinases. In this study, we explored the
tyrosinase inhibitory effects of 2,3-diphenylacrylic
acid (2,3-DPA) derivatives, which also possess the (E)-β-phenyl-α,β-unsaturated carbonyl motif. We synthesized fourteen (E)-2,3-DPA derivatives 1a-1n and one (Z)-2,3-DPA-derivative 1l' using a Perkin reaction with
phenylacetic acid and appropriate substituted
benzaldehydes. In our mushroom
tyrosinase assay, 1c showed higher
tyrosinase inhibitory activity (76.43 ± 3.53%, IC50 = 20.04 ± 1.91 µM) with than the other 2,3-DPA derivatives or
kojic acid (21.56 ± 2.93%, IC50 = 30.64 ± 1.27 μM). Our mushroom
tyrosinase inhibitory results were supported by our docking study, which showed compound 1c (-7.2 kcal/mole) exhibited stronger binding affinity for mushroom
tyrosinase than
kojic acid (-5.7 kcal/mole). In B16F10
melanoma cells (a murine cell-line), 1c showed no cytotoxic effect up to a concentration of 25 μM and exhibited greater
tyrosinase inhibitory activity (68.83%) than
kojic acid (49.39%). In these cells,
arbutin (a well-known
tyrosinase inhibitor used as the positive control) only inhibited
tyrosinase by 42.67% even at a concentration of 400 μM. Furthermore, at 25 µM, 1c reduced
melanin contents in B16F10
melanoma cells by 24.3% more than
kojic acid (62.77% vs. 38.52%). These results indicate 1c is a promising candidate treatment for pigmentation-related diseases and potential
skin whitening agents.